Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Liulu ZhangZhiyong WuJie LiDongqin ZhuLingling YangYang ShaoYing LinZhenzhen LiuYin CaoGangling ZhangShiyao ShangYi ZhangKun WangPublished in: JCO precision oncology (2023)
HRD is a potential predictive biomarker for clinical benefit from neoadjuvant carboplatin-based chemotherapy and provides a possibility for screening the optimum chemotherapy backbone to combine with immunotherapy.